Norway Peanut Allergy Treatment Market Size & Outlook
Norway peanut allergy treatment market, 2018-2030 (US$M)
Related Markets
Norway peanut allergy treatment market highlights
- The Norway peanut allergy treatment market generated a revenue of USD 0.8 million in 2023 and is expected to reach USD 1.6 million by 2030.
- The Norway market is expected to grow at a CAGR of 11.2% from 2024 to 2030.
- In terms of segment, epinephrine was the largest revenue generating drug class in 2023.
- Immunotherapies is the most lucrative drug class segment registering the fastest growth during the forecast period.
Peanut allergy treatment market data book summary
| Market revenue in 2023 | USD 0.8 million |
| Market revenue in 2030 | USD 1.6 million |
| Growth rate | 11.2% (CAGR from 2023 to 2030) |
| Largest segment | Epinephrine |
| Fastest growing segment | Immunotherapies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Antihistamines, Epinephrine, Immunotherapies, Other Drug Class |
| Key market players worldwide | Nestle SA, Sanofi SA, DBV Technologies SA ADR, PureTech Health PLC, Regeneron Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd ADR, Protagonist Therapeutics Inc, Aravax, Alladapt Immunotherapeutics |
Other key industry trends
- In terms of revenue, Norway accounted for 0.2% of the global peanut allergy treatment market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK peanut allergy treatment market is projected to lead the regional market in terms of revenue in 2030.
- Italy is the fastest growing regional market in Europe and is projected to reach USD 25.7 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Peanut Allergy Treatment Market Scope
Peanut Allergy Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Norway peanut allergy treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peanut allergy treatment market will help companies and investors design strategic landscapes.
Epinephrine was the largest segment with a revenue share of 50% in 2023. Horizon Databook has segmented the Norway peanut allergy treatment market based on antihistamines, epinephrine, immunotherapies, other drug class covering the revenue growth of each sub-segment from 2018 to 2030.
A study published in 2022 by NCBI reveals that in Norway, the prevalence of peanut allergy is estimated to be 0.4%. This data indicates that peanut allergies in Norway are relatively uncommon, affecting a small percentage of the population.
Although the prevalence may not be high, it is essential to recognize that even a low percentage can translate to a significant number of individuals living with peanut allergies. Understanding the trend of this disease is crucial for healthcare professionals & stakeholders in the market to provide appropriate care and treatment for those affected by peanut allergies in Norway.
Reasons to subscribe to Norway peanut allergy treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Norway peanut allergy treatment market databook
-
Our clientele includes a mix of peanut allergy treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway peanut allergy treatment market , including forecasts for subscribers. This country databook contains high-level insights into Norway peanut allergy treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Norway peanut allergy treatment market size, by drug class, 2018-2030 (US$M)
Norway Peanut Allergy Treatment Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
